Daniel O'Day

Type: Person

Name: Daniel O'Day

First reported May 15 2013 - Updated May 15 2013 - 1 reports

erlotinib

Roche wins new targeted OK for Tarceva in EGFR-positive lung cancer

Diagnostic test to identify EGFR patients also gets FDA approvalShareToolsRoche's ($RHHBY) targeted-drug crusade marches on. Along with its partner, Astellas, the company won FDA approval for a new, first-line use for its lung cancer drug Tarceva in patients ... [Published FiercePharma - May 15 2013]

Entities: erlotinib, Roche Holding AG, Lung Cancer, Patient

First reported Apr 14 2013 - Updated Apr 14 2013 - 2 reports

Roche Holding Earnings Call Insights: Pipeline Details and Kadcyla Outlook

Roche Holding (RHHBY) recently reported its first quarter earnings and discussed the following topics in its earnings conference call.Pipeline DetailsTimothy Anderson – Sanford C. Bernstein & Co., LLC : My questions, all have to do with the pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013]

Entities: Kadcyla, Roche Holding AG, Gantenerumab, Daniel O'Day

First reported Apr 11 2013 - Updated Apr 11 2013 - 1 reports

Alan Hippe

Roche Holding AG, Q1 2013 Sales/ Trading Statement Call, Apr 11, 2013

Roche Holding Ltd ( RHHBY.OB ) April 11, 2013 8:00 am ET Executives Severin Schwan - Chief Executive Officer and Director Daniel O'Day - Chief Executive Officer of Roche Molecular Diagnostics and President of Roche Molecular Diagnostics Roland ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 11 2013]

Entities: Roche Holding AG, Roche Molecular Diagnostics, Eric Le Berrigaud, Alan Hippe, Michael Leuchten

First reported Feb 27 2013 - Updated Feb 27 2013 - 1 reports

Roche Holding AG

Which bit of All and Trials don't Roche understand?

Drug firm Roche pledges greater access to trials data26 February 2013 Last updated at 18:00Research suggests half of all clinical trials have never been publishedThe pharmaceutical company Roche has announced that it will make more of the data from its ... [Published PharmaGossip - Feb 27 2013]

Entities: Roche Holding AG, Clinical trials, Tamiflu, Daniel O'Day

Quotes

Daniel O'Day, Chief Operating Officer of Roche Pharma said: "we understand and support calls for our industry to be more transparent about clinical trial data with the aim of meeting the best interests of patients and medicine."

Which bit of All and Trials don't Roche understand? [Published PharmaGossip - Feb 27 2013]

More Content

sort by: Date \| Relevance
Roche wins new targeted OK for Tarceva in EGFR-... [Published FiercePharma - May 15 2013]
Roche Holding Earnings Call Insights: Pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013]
Roche Holding Earnings Call Insights: Pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013]
Roche Holding AG, Q1 2013 Sales/ Trading Statem... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 11 2013]
Which bit of All and Trials don't Roche underst... [Published PharmaGossip - Feb 27 2013]
Roche Peels Back The Curtain On Clinical Trial ... [Published Pharmalot - Feb 26 2013]
Roche Holding AG Management Discusses 2012 Resu... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 31 2013]
Roche Offers Compromise On Tamiflu Data Fight [Published Pharmalot - Nov 26 2012]
Daniel OâDay appointed as COO of Roche Pharma [Published PharmaBiz - Aug 28 2012]

Blogs

sort by: Date \| Relevance
Roche Holding Earnings Call Insights: Pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013] Roche Holding (RHHBY) recently reported its first quarter earnings and discussed the following topics in its earnings conference call.Pipeline DetailsTimothy Anderson – Sanford C. Bernstein & Co., LLC : My questions, all have to do with the pipeline ...
Roche Holding Earnings Call Insights: Pipeline ... [Published Wall St. Cheat Sheet - Apr 14 2013] Roche Holding (RHHBY) recently reported its first quarter earnings and discussed the following topics in its earnings conference call. Pipeline Details Timothy Anderson – Sanford C. Bernstein & Co., LLC: My questions, all have to do with the pipeline ...
Which bit of All and Trials don't Roche underst... [Published PharmaGossip - Feb 27 2013] Drug firm Roche pledges greater access to trials data26 February 2013 Last updated at 18:00Research suggests half of all clinical trials have never been publishedThe pharmaceutical company Roche has announced that it will make more of the data from its ...
Roche Peels Back The Curtain On Clinical Trial ... [Published Pharmalot - Feb 26 2013] In response to enormous criticism over its handling of Tamiflu clinical trial data, Roche announced a new plan to increase access to such information and its approach mimics steps begun recently by GlaxoSmithKline. Specifically, Roche will work with ...
Roche Offers Compromise On Tamiflu Data Fight [Published Pharmalot - Nov 26 2012] In a bid to fend off its critics, Roche is offering to establish a multi-party advisory board to review all data for its Tamiflu influenza medication. The board would consist of experts from academia and private institutions, who would then agree on ...